EcoMed

OncoMed Pharmaceuticals was a clinical-stage biotechnology company focused on discovering and developing first-in-class protein therapeutics targeting cancer stem cells (CSCs) and immuno-oncology pathways. The company's pipeline was built on a proprietary platform designed to identify and characterize CSCs, leading to the development of antibodies targeting the Notch and Wnt signaling pathways. OncoMed established significant strategic alliances with major pharmaceutical companies, including Celgene and Bayer, to advance its therapeutic candidates. Following several clinical setbacks in its lead programs, the company underwent a strategic review and was ultimately acquired by Mereo BioPharma in 2019.